Also known as STELARA®.
Quarterly sales topped $25.3B; adjusted net earnings and EPS rose, free cash flow improved, and full-year revenue guidance was raised above $100B for the first time.
sBLA submitted for STELARA to treat pediatric ulcerative colitis, backed by Phase 3 UNIFI Jr trial data, aiming to expand treatment options for children.
